Tocilizumab is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData, Phase II drugs for Non-Small Cell Lung Cancer have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tocilizumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tocilizumab overview
Tocilizumab (Actemra / Roactemra) is a humanized monoclonal antibody, acts as immunosupressant preparation. It is formulated as injectable solution and solution concentrate for intravenous, intravenous drip or subcutaneous route of administration. Actemra is indicated for the treatment of rheumatoid arthritis in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying anti-rheumatic drugs via intravenous and subcutaneous route. Tocilizumab intravenous route is indicated for the treatment of polyarticular juvenile idiopathic arthritis (PJIA) and systemic juvenile idiopathic arthritis in patients of 2 years age and older. Roactemra, in combination with methotrexate (MTX), is indicated for the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX. It is also indicated to treat adults with temporal arteritis, takayasu arteritis, and vasculitis, for the treatment of cytokine release syndrome induced by tumor-specific T cell infusion therapy. Actemra (tocilizumab) is used as emergency treatment for coronavirus disease 2019 (COVID-19) in hospitalized adults and pediatric patients (2 years of age and older) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). Actemra is indicated for the treatment of pneumonia caused by SARS-CoV-2
The drug candidate is under development for the treatment of follicular lymphoma, metastatic hepatocellular carcinoma, non-small cell lung cancer, systemic sclerosis large-vessel vasculitis, giant cell arteritis, polymyalgia rheumatica, Behcet’s Uveitis, granulomatosis with polyangiitis, Schnitzler syndrome, pain, familial mediterranean fever, multiple myeloma (kahler disease) and diffuse large b-cell lymphoma. It is also under development for COVID-19 pneumonia and in hospitalized adult patients with severe COVID-19, sepsis and septic shock.
It was also under development for the treatment of idiopathic retroperitoneal fibrosis, pulmonary arterial hypertension, Grave's orbitopathy or thyroid eye disease, ankylosing spondylitis, giant lymph node hyperplasia and metastatic pancreatic cancer, polymyositis, dermatomyositis, amyotrophic lateral sclerosis and B-Cell Chronic Lymphocytic Leukemia.
F. Hoffmann-La Roche overview
F. Hoffmann-La Roche (Roche) is a biotechnology company and a provider of in-vitro diagnostics as well as a supplier of transformative innovative solutions across major disease areas. It provides drugs for the treatment of cancer, other auto-immune diseases, central nervous system disorders, ophthalmological disorders, infectious diseases, and respiratory diseases. The company also offers in vitro diagnostics, tissue-based cancer diagnostics, and diabetes management solutions. Roche conducts research to identify novel methods to prevent, diagnose, and treat diseases. The company offers its products and services to hospitals, healthcare professionals, commercial laboratories, researchers and pharmacists. Roche is headquartered in Basel, Switzerland.
For a complete picture of Tocilizumab’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
